학술논문
Anticoagulation control among patients on vitamin K antagonists in nine countries in Sub-Saharan Africa
Document Type
Original Paper
Author
Mwita, Julius Chacha; Francis, Joel Msafiri; Pillay, Chriselda; Ogah, Okechukwu S.; Goshu, Dejuma Yadeta; Agyekum, Francis; Musonda, John Mukuka; James, Maduka Chiedozie; Tefera, Endale; Kabo, Tsie; Ditlhabolo, Keolebile Irene; Ndlovu, Kagiso; Ayodele, Ayoola Yekeen; Mkomanga, Wigilya P.; Chillo, Pilly; Damasceno, Albertino; Folson, Aba Ankomaba; Oyekunle, Anthony; Tebuka, Erius; Kalokola, Fredrick; Forrest, Karen; Dunn, Helena; Karaye, Kamilu; Jean-Pierre, Fina Lubaki; Oljira, Chala Fekadu; Tadesse, Tamirat Assefa; Taiwo, Tolulope Shogade; Nwafor, Chibuike E.; Omole, Olufemi; Anakwue, Raphael; Cohen, Karen
Source
Journal of Thrombosis and Thrombolysis: A Journal for Translation, Application and Therapeutics in Thrombosis and Vascular Science. 57(4):613-621
Subject
Language
English
ISSN
1573-742X
Abstract
Vitamin K antagonists (VKA) is the primary anticoagulant in most settings of Sub-Saharan Africa. Understanding the quality of anticoagulation services in the continent is vital in optimising the intended benefits. This study assessed the quality of anticoagulation and associated factors among VKA-treated patients in nine SSA countries. We conducted a retrospective cohort study of randomly selected patients on anticoagulation from 20 clinics in Botswana, the Democratic Republic of Congo, Ethiopia, Gambia, Ghana, Mozambique, Nigeria, Tanzania, and South Africa. Eligible participants were those on VKAs for at least three months and with at least four international normalised ratios (INR) results in 2019–2021. We report the proportion of INR values in the therapeutic range, time-in-therapeutic range (TTR) using the Rosendaal method, and the proportion of patients with TTR ≥ 65% (optimal anticoagulation). The mean age was 51.1(16.1) years, and 64.2% were women. The most common indications for VKA included venous thromboembolism (29.6%), prosthetic valves (26.7%) and atrial fibrillation/flutter (30.1%). We analysed 6743 INR tests from 1011 participants, and of these, 48.5% were sub-therapeutic, 34.1% therapeutic, and 17.4% were supratherapeutic relative to disease-specific reference ranges. TTR was calculated for 660 patients using 4927 INR measurements. The median (interquartile range [IQR]) TTR was 35.8(15.9,57.2) %. Optimal anticoagulation control was evident in 19.2% of participants, varying from 2.7% in Tanzania to 23.1% in Ethiopia. The proportion of patients with TTR ≥ 65% was 15,4% for prosthetic heart valves, 21.1% for venous thromboembolism and 23.7% for atrial fibrillation or flutter. Countries with universal health coverage had higher odds of optimal anticoagulation control (adjusted odds ratio (aOR) 1.79, 95% confidence interval [CI], 1.15– 2.81, p = 0.01). Patients on VKAs for different therapeutic indications in SSA had suboptimal TTR. Universal health coverage increased the odds of achieving TTR by 79%. The evidence calls for more intensive warfarin management strategies in SSA, including providing VKA services without out-of-pocket payments.